Critical Care Nephrology – Research Article

Alarcia-Lacalle A.a,b· Barrasa H.b,c· Maynar J.b,c· Canut-Blasco A.b,d· Solinís M.Á.a,b· Isla A.a,b· Rodríguez-Gascón A.a,b

Author affiliations

aPharmacokinetic, Nanotechnology and Gene Therapy Group (PharmaNanoGene), Faculty of Pharmacy, Centro de Investigación Lascaray Ikergunea, University of the Basque Country UPV/EHU, Vitoria-Gasteiz, Spain
bBioaraba, Microbiology, Infectious Disease, Antimicrobial Agents, and Gene Therapy, Vitoria-Gasteiz, Spain
cOsakidetza Basque Health Service, Araba University Hospital, Intensive Care Unit, Vitoria-Gasteiz, Spain
dOsakidetza Basque Health Service, Araba University Hospital, Microbiology Service, Vitoria-Gasteiz, Spain

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent via DeepDyve Unlimited fulltext viewing of this article Organize, annotate and mark up articles Printing and downloading restrictions apply

Start free trial

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview

Received: October 07, 2022
Accepted: January 08, 2023
Published online: March 01, 2023

Number of Print Pages: 10
Number of Figures: 3
Number of Tables: 4

ISSN: 0253-5068 (Print)
eISSN: 1421-9735 (Online)

For additional information: https://www.karger.com/BPU

Abstract

Introduction: Continuous renal replacement therapies (CRRTs) are frequently used in critically ill patients; however, there are scarce in vitro and in vivo studies showing the extracorporeal elimination of ceftaroline and avibactam. The aim of this study was to assess, through an in vitro model, the extracorporeal elimination of ceftaroline and avibactam by continuous veno-venous hemofiltration (CVVH), continuous veno-venous hemodiafiltration (CVVHDF), and continuous veno-venous hemodialysis (CVVHD), using a polysulfone hemofilter. Methods: Simulated in vitro experiments were performed using a multiFiltrate machine with a 1.4 m2 Ultraflux® AV600S polysulfone hemofilter. Isofundin® without or with bovine serum albumin was circulated as vehicle for ceftaroline or avibactam. Pre-filter, post-filter, and effluent samples were taken over a period of 60 min, and they were immediately stored at 4°C until processed in the same day. The quantification of ceftaroline and avibactam in the samples was performed by high-performance liquid chromatography with ultraviolet detection. Protein binding, extraction coefficient (EC), and extracorporeal clearance (CLCRRT) were calculated. Results: The elimination of both ceftaroline and avibactam during the three extracorporeal modalities followed first-order pharmacokinetics. Regardless of the CRRT technique, EC values for both molecules were around 1, similar to the unbound fraction of avibactam (0.96) and higher than the unbound fraction of ceftaroline (0.79). CLCRRT of ceftaroline ranged from 15.63 to 17.66 mL/min when CVVH and CVVHD were used with a flow rate of 1,000 mL/h, and from 29.25 to 32.95 mL/min for the CVVHDF modality with a flow rate of 2,000 mL/h. For avibactam, CLCRRT ranged from 15.07 to 18.82 mL/min for CVVH and CVVHD, and from 33.74 to 34.13 mL/min for CVVHDF. Discussion: Avibactam and ceftaroline are extensively removed through the polysulfone membrane, and a dose adjustment may be recommended for patients under CRRT to ensure pharmacodynamic target achievement.

© 2023 S. Karger AG, Basel

References Samoni S, Husain-Syed F, Villa G, Ronco C. Continuous renal replacement therapy in the critically ill patient: from garage technology to artificial intelligence. J Clin Med. 2021;11(1):172. Li L, Li X, Xia Y, Chu Y, Zhong H, Li J, et al. Recommendation of antimicrobial dosing optimization during continuous renal replacement therapy. Front Pharmacol. 2020;11:1–16. Pea F, Viale P, Pavan F, Furlanut M. Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy. Clin Pharmacokinet. 2007;46(12):997–1038. Gorman SK, Slavik RS, Lam S. Presence and accuracy of drug dosage recommendations for continuous renal replacement therapy in tertiary drug information references. Can J Hosp Pharm. 2012;65(3):188–95. Eastman C, Erstad BL. Availability of information for dosing commonly used medications in special ICU populations. Am J Health Syst Pharm. 2020;77(7):529–34. Zhanel GG, Sniezek G, Schweizer F, Zelenitsky S, Lagacé-Wiens PRS, Rubinstein E, et al. Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus. Drugs. 2009;69(7):809–31. U.S. Department. Of health and human services. Food and Drug Administration. Teflaro. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/200327s016s017lbl.pdf (accessed on 31 May, 2022). European Medicines Agency. Science Medicines health. Zinforo. Available online: https://www.ema.europa.eu/en/medicines/human/EPAR/zinforo (accesed on 31 May, 2022). Mckew G, Merlino J, Beukers A, Van Hal S, Gottlieb T. Success of ceftazidime-avibactam and aztreonam in combination for a refractory biliary infection with recurrent bacteraemia due to blaIMP-4 carbapenemase-producing Enterobacter hormaechei subsp. oharae. Access Microbiol. 2021;3(8):000248. Bassetti M, Giacobbe DR, Castaldo N, Russo A, Vena A. Role of new antibiotics in extended-spectrum β-lactamase-AmpC- infections. Curr Opin Infect Dis. 2021;34(6):748–55. Kiang TKL, Wilby KJ, Ensom MHH. A critical review on the clinical pharmacokinetics, pharmacodynamics, and clinical trials of ceftaroline. Clin Pharmacokinet. 2015;54(9):915–31. National Center for Biotechnology Information. PubChem compound summary for CID 9852981, ceftaroline fosamil. Available online: https://pubchem.ncbi.nlm.nih.gov/compound/Ceftaroline-fosamil (accessed on 21 November, 2022). Gatti M, Pea F. Antimicrobial dose reduction in continuous renal replacement therapy: myth or real need? A practical approach for guiding dose optimization of novel antibiotics. Clin Pharmacokinet. 2021;60(10):1271–89. National Center for Biotechnology Information. PubChem compound summary for CID 9835049, avibactam. Available online: https://pubchem.ncbi.nlm.nih.gov/compound/9835049 (accessed on 21 November, 2022). Drugbank. Available online: https://go.drugbank.com/drugs/DB09060 (accessed on 21 November, 2022). Kalaria S, Williford S, Guo D, Shu Y, Medlin C, Li M, et al. Optimizing ceftaroline dosing in critically ill patients undergoing continuous renal replacement therapy. Pharmacotherapy. 2021;41(2):205–11. Soukup P, Faust AC, Edpuganti V, Putnam WC, McKinnell JA. Steady-State ceftazidime-avibactam serum concentrations and dosing recommendations in a critically ill patient being treated for Pseudomonas aeruginosa pneumonia and undergoing continuous venovenous hemodiafiltration. Pharmacotherapy. 2019;39(12):1216–22. Wenzler E, Bunnell KL, Bleasdale SC, Benken S, Danziger LH, Rodvold KA. Pharmacokinetics and dialytic clearance of ceftazidime-avibactam in a critically ill patient on continuous venovenous hemofiltration. Antimicrob Agents Chemother. 2017;61(7):e00464–17. Alarcia-Lacalle A, Barrasa H, Maynar J, Canut-Blasco A, Gómez-González C, Solinís MÁ, et al. Quantification of ceftaroline in human plasma using high-performance liquid chromatography with ultraviolet detection: application to pharmacokinetic studies. Pharmaceutics. 2021;13(7):959. Churchwell MD. Use of an in vitro model of renal replacement therapy systems to estimate extracorporeal drug removal. J Clin Pharmacol. 2012;52(1 Suppl l):35S–44S. Arzuaga A, Maynar J, Gascón AR, Isla A, Corral E, Fonseca F, et al. Influence of renal function on the pharmacokinetics of piperacillin/tazobactam in intensive care unit patients during continuous venovenous hemofiltration. J Clin Pharmacol. 2005;45(2):168–76. Nalesso F, Claudio R. Selecting a dialyzer. Handbook of dialysis therapy, 2017. Vols. 227–238; p. e4. Jang SM, Awdishu L. Drug dosing considerations in continuous renal replacement therapy. Semin Dial. 2021;34(6):480–8. Golper TA. Update on drug sieving coefficients and dosing adjustments during continuous renal replacement therapies. Contrib Nephrol. 2001;132:349–53. Farrar JE, Mueller SW, Stevens V, Kiser TH, Taleb S, Reynolds PM. Correlation of antimicrobial fraction unbound and sieving coefficient in critically ill patients on continuous renal replacement therapy: a systematic review. J Antimicrob Chemother. 2022;77(2):310–9. Riccobene T, Jakate A, Rank D. A series of pharmacokinetic studies of ceftaroline fosamil in select populations: normal subjects, healthy elderly subjects, and subjects with renal impairment or end-stage renal disease requiring hemodialysis. J Clin Pharmacol. 2014;54(7):742–52. Schetz M, Lauwers P, Van den Berghe G, Verwaest C, Ferdinande P, Van Den Berghe G. Pharmacokinetics of continuous renal replacement therapy. Intensive Care Med. 1995;21(7):612–20. Isla A, Arzuaga A, Maynar J, Gascón AR, Solinís MA, Corral E, et al. Determination of ceftazidime and cefepime in plasma and dialysate-ultrafiltrate from patients undergoing continuous veno-venous hemodiafiltration by HPLC. J Pharm Biomed Anal. 2005;39(5):996–1005. Isla A, Gascón AR, Maynar J, Arzuaga A, Sánchez-Izquierdo JA, Pedraz JL. In vitro AN69 and polysulfone membrane permeability to ceftazidime and in vivo pharmacokinetics during continuous renal replacement therapies. Chemotherapy. 2007;53(3):194–201. Shields RK, Nguyen MH, Chen L, Press EG, Kreiswirth BN, Clancy CJ. Pneumonia and renal replacement therapy are risk factors for ceftazidime-avibactam treatment failures and resistance. Antimicrob Agents Chemother. 2018;62(5):1–12. Isla A, Rodríguez-Gascón A, Trocóniz IF, Bueno L, Solinís MÁ, Maynar J, et al. Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy. Clin Pharmacokinet. 2008;47(3):173–80. Barrasa H, Soraluce A, Isla A, Martín A, Maynar J, Canut A, et al. Pharmacokinetics of linezolid in critically ill patients on continuous renal replacement therapy: influence of residual renal function on PK/PD target attainment. J Crit Care. 2019;50:69–76. Gatti M, Pea F. Pharmacokinetic/pharmacodynamic target attainment in critically ill renal patients on antimicrobial usage: focus on novel beta-lactams and beta lactams/beta-lactamase inhibitors. Expert Rev Clin Pharmacol. 2021;14(5):583–99. Chen J, Li S, Wang Q, Wang C, Qiu Y, Yang L, et al. Optimizing antimicrobial dosing for critically ill patients with MRSA infections: a new paradigm for improving efficacy during continuous renal replacement therapy. Pharmaceutics. 2022;14(4):842. Riccobene TA, Su SF, Rank D. Single- and multiple-dose study to determine the safety, tolerability, and pharmacokinetics of ceftaroline fosamil in combination with avibactam in healthy subjects. Antimicrob Agents Chemother. 2013;57(3):1496–504. Article / Publication Details

First-Page Preview

Received: October 07, 2022
Accepted: January 08, 2023
Published online: March 01, 2023

Number of Print Pages: 10
Number of Figures: 3
Number of Tables: 4

ISSN: 0253-5068 (Print)
eISSN: 1421-9735 (Online)

For additional information: https://www.karger.com/BPU

Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.